Anti-HIV pill not cost effective among U.S. drug abusers

By Andrew M. Seaman (Reuters Health) – Providing anti-HIV pills to people who abuse injection drugs in the U.S. would reduce infections and save lives but end up costing the healthcare system billions of dollars a year, researchers say. The message for policymakers is that pre-exposure prophylaxis (PrEP) use among injection drug abusers is effective, but very costly, said study author Dr. Douglas Owens. Currently, the daily pill known as Truvada, manufactured by Gilead, is the only form of PrEP approved by the U.S. Food and Drug Administration.
Sexual Health News Headlines – Yahoo! News